SHG based screening assay for detecting effectors of brain localized GPCRs that can be used to probe mental illness related phenotypes

Information

  • Research Project
  • 9778443
  • ApplicationId
    9778443
  • Core Project Number
    R43MH119906
  • Full Project Number
    1R43MH119906-01
  • Serial Number
    119906
  • FOA Number
    PA-18-708
  • Sub Project Id
  • Project Start Date
    5/10/2019 - 5 years ago
  • Project End Date
    4/30/2021 - 3 years ago
  • Program Officer Name
    GRABB, MARGARET C
  • Budget Start Date
    5/10/2019 - 5 years ago
  • Budget End Date
    4/30/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    01
  • Suffix
  • Award Notice Date
    5/10/2019 - 5 years ago
Organizations

SHG based screening assay for detecting effectors of brain localized GPCRs that can be used to probe mental illness related phenotypes

Abstract Biodesy has developed the Biodesy Delta device, a platform based on second harmonic generation (SHG) that allows one to measure changes in biomolecule structure upon ligand binding in real-time and in a high- throughput manner (using multi well plates). The Biodesy Delta will be used to develop a novel, high- throughput, SHG-based, commercial screening platform for identifying new binders and studying known ligands that directly modulate the structure and function of G-protein coupled receptors (GPCRs). SHG is a non-linear optical process that is highly sensitive to orientational changes of a SH-active, 370Da dye probe, covalently attached to a protein of interest, and requires very small amount of protein to get a reading. Using SHG, Biodesy has measured a range of molecular interactions between target proteins and small molecules, fragments, peptides and antibodies. To enable the study of GPCRs, we have successfully developed a prototype surface that allows tethering proteins and is resistant to detergents used to solubilize and stabilize membrane protein samples in solution. The new plate surface demonstrated minimal non-specific binding of the purified, labeled, thermostabilized, neurotensin receptor 1 (NTR1) GPCR. We have also demonstrated that SHG dye labeled NTR1 tethered to the surface remains functional by examining the binding of two control ligands to the tethered protein. In this project, we will develop a SHG assay that can be utilized for GPCRs that have not been stabilized by mutagenesis, and are relevant targets for drug discovery efforts or require a more in-depth understanding of their function. The Adenosine A2A Receptor (A2AR) will be the model GPCR, due to the large amount of structural, biophysical and biochemical data, functional assays and a non-stabilized construct that we can use for our SHG assay validation. First, we will design and test for activity with the Biodesy Delta multiple A2AR constructs that differ in the length of the C-terminal tail, which is very flexible and can interfere with binding to the surface. This will allow us to choose the optimal A2AR that retains full activity after labeling for SHG and attachment to the well surface. We will then create a version of our assay that can utilize 1536-well plates for more efficient screening of chemical libraries. Finally, we will test our assay in a proof of concept screen of a library that contains 20,000 small molecules.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R43
  • Administering IC
    MH
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    279745
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
  • Funding ICs
    NIMH:279745\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIODESY, INC
  • Organization Department
  • Organization DUNS
    169610016
  • Organization City
    SOUTH SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940806102
  • Organization District
    UNITED STATES